Viloxazine
Viloxazine
Viloxazine (pronounced: vi-lox-a-zine) is a Selective Norepinephrine Reuptake Inhibitor (NRI) that was previously used as an antidepressant. Viloxazine was discovered and developed in the 1970s by Imperial Chemical Industries (ICI), which merged into AstraZeneca in 1993.
Etymology
The term "Viloxazine" is derived from the systematic (IUPAC) name: 2-[(2-Ethoxyphenoxy)methyl]morpholine. The name is a combination of parts of its chemical structure, which includes a morpholine ring and an ethoxyphenyl group.
Usage
Viloxazine was used in some European countries for the treatment of depression until it was discontinued due to unprofitability. It is currently being investigated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy by Supernus Pharmaceuticals.
Mechanism of Action
Viloxazine inhibits the reuptake of norepinephrine, thereby increasing the amount of norepinephrine in the brain. This is thought to help alleviate symptoms of depression and ADHD.
Related Terms
- Selective Norepinephrine Reuptake Inhibitor (NRI)
- Antidepressant
- Depression
- Attention Deficit Hyperactivity Disorder (ADHD)
- Narcolepsy
External links
- Medical encyclopedia article on Viloxazine
- Wikipedia's article - Viloxazine
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski